November 5, 2019 / 6:19 AM / 16 days ago

BRIEF-Sandoz Receives FDA Approval For Oncology Supportive Care Ziextenzo

Nov 5 (Reuters) - Novartis AG:

* SANDOZ RECEIVES US FDA APPROVAL FOR LONG-ACTING ONCOLOGY SUPPORTIVE CARE BIOSIMILAR ZIEXTENZO™ (PEGFILGRASTIM-BMEZ)

* ZIEXTENZO™ IS INDICATED TO DECREASE INCIDENCE OF FEBRILE NEUTROPENIA, ONE OF MOST SERIOUS SIDE EFFECTS OF CHEMOTHERAPY

* WITH APPROVAL OF ZIEXTENZO™ , SANDOZ IS FIRST AND ONLY COMPANY TO OFFER US PHYSICIANS LONG- AND SHORT-ACTING FILGRASTIM BIOSIMILAR TREATMENT OPTIONS

* SANDOZ NOW INTENDS TO LAUNCH ZIEXTENZO IN US AS SOON AS POSSIBLE THIS YEAR Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below